Enterprise Value
1.876B
Cash
791.3M
Avg Qtr Burn
-101.4M
Short % of Float
14.53%
Insider Ownership
1.21%
Institutional Own.
93.31%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
NTLA-2001 (CRISPR/Cas9) Details Transthyretin amyloidosis, Transthyretin Amyloid Cardiomyopathy, Cardiomyopathy | Phase 3 Update | |
NTLA-2001 (CRISPR/Cas9) Details Hereditary transthyretin amyloidosis, Polyneuropathy | Phase 3 Initiation | |
NTLA-2002 (KLKB1 Inhibitor) Details Hereditary angioedema , Rare diseases, Rare genetic disease | Phase 1/2 Data readout | |
NTLA-3001 Details Alpha-1 Antitrypsin Deficiency, Lung disease | Phase 1 Initiation | |
NTLA-5001 Details Acute myeloid leukemia | Failed Discontinued | |
OTQ923 / HIX763 (Hematopoietic Stem Cells (HSC)) Details Sickle cell disease | Failed Discontinued |